Evidence map›Paper›PMID 31177384›Full record

ArticleCEN case reports2019

Atypical reduction of plasma ADAMTS13 activity by a non-IgG-type inhibitor in a patient with hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli.

Shinya Nakayama, Shuma Hirashio, Haruka Yorishima, Toshiki Doi, Yoko Yoshida, Masanori Matsumoto, Takao Masaki

Open access · bronzeAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in CEN case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Shinya NakayamaDepartment of Nephrology, Hiroshima University Hospital, Hiroshima, Japan.
Shuma HirashioDepartment of Nephrology, Hiroshima University Hospital, Hiroshima, Japan.
Haruka YorishimaDepartment of Nephrology, Hiroshima University Hospital, Hiroshima, Japan.
Toshiki DoiDepartment of Nephrology, Hiroshima University Hospital, Hiroshima, Japan.
Yoko YoshidaDivision of Nephrology and Endocrinology, The University of Tokyo Hospital, Tokyo, Japan.
Masanori MatsumotoDepartment of Blood Transfusion Medicine, Nara Medical University, Kashihara, Japan.
Takao MasakiDepartment of Nephrology, Hiroshima University Hospital, Hiroshima, Japan. masakit@hiroshima-u.ac.jp.ORCID 0000-0003-4271-9964
Hiroshima University Hospital · JPNara Medical University · JPUniversity of Tokyo Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thrombotic microangiopathies include hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP). Measurement of plasma levels of "a disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13" (ADAMTS13) activity can distinguish HUS from TTP. Reduced plasma ADAMTS13 activity (< 10% normal range) is atypical for HUS, but not for TTP. However, we detected reduced ADAMTS13 activity in a patient with Shiga toxin-producing Escherichia coli-associated HUS caused by non-IgG anti-ADMTS13 autoantibodies. Furthermore, the patient exhibited possible genetic abnormalities associated with atypical HUS. The patient fully recovered after administration of supportive therapy. To the best of our knowledge, very few cases of STEC-HUS with reduced ADAMTS13 activity have been reported; thus far, none have described the presence of non-IgG anti-ADMTS13 autoantibodies. Therefore, we suggest that anti-ADAMTS13 analyses should be performed in patients diagnosed with STEC-HUS, especially in those who present with prolonged healing or unexpected clinical symptoms.

Indexed as

ADAMTS13 ProteinAutoantibodiesDisintegrinsErythrocyte TransfusionFemaleHemolytic-Uremic SyndromeHumansInfusions, IntravenousMembrane Cofactor ProteinPurpura, Thrombotic ThrombocytopenicRenal InsufficiencySeverity of Illness IndexShiga-Toxigenic Escherichia coliThrombotic MicroangiopathiesTreatment OutcomeYoung AdultADAMTS13 ProteinADAMTS13 protein, humanAutoantibodiesDisintegrinsMembrane Cofactor ProteinA disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13Atypical hemolytic uremic syndromeShiga toxin-producing Escherichia coli-associated hemolytic uremic syndromeThrombotic microangiopathyThrombotic thrombocytopenic purpura

Identifiers

PMID31177384
PMCPMC6820649
OpenAlexW2955856886

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.